AR042653A1 - Derivados sustiuidos de 1- piperidin -3- il- 4- piperidin 4- -il- piperazina y su uso como antagonistas de taquiquininas - Google Patents
Derivados sustiuidos de 1- piperidin -3- il- 4- piperidin 4- -il- piperazina y su uso como antagonistas de taquiquininasInfo
- Publication number
- AR042653A1 AR042653A1 ARP030104779A ARP030104779A AR042653A1 AR 042653 A1 AR042653 A1 AR 042653A1 AR P030104779 A ARP030104779 A AR P030104779A AR P030104779 A ARP030104779 A AR P030104779A AR 042653 A1 AR042653 A1 AR 042653A1
- Authority
- AR
- Argentina
- Prior art keywords
- disorders
- alkyl
- group
- halo
- optionally substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Addiction (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
La presente se refiere a derivados sustituidos de 1piperidin-3-il-4-piperidin-4-il-piperazina que tienen actividad antagonista de las neuroquininas, en particular actividad antagonista de NK1, una actividad antagonista combinada de NK1/NK3, y una actividad antagonista combinada de NK1/NK2/NK3, a su preparación a las composiciones que los comprenden y a su uso como medicamento, en particular para el tratamiento de la esquizofrenia, emesis, ansiedad y depresión, síndrome de intestino irritable (IBS), trastornos de ritmo circadiano, dolor visceral, inflamación neurogénica, asma, desórdenes de la micturación tales como incontinencia urinaria y nocicepción. En vista de su capacidad para antagonizar las acciones de las taquininas por bloqueo de los receptores de neuroquininas, y en particular antagonizar las acciones de la sustancia P, Neuroquinina A y neuroquinina B por bloqueo del receptor NK1, NK2 y NK3, los compuestos de acuerdo con la presente son útiles como medicamentos, en particular en el tratamiento profiláctico y terapéutico de condiciones intermediadas por taquininas, tales como, por ejemplo, trastornos del SNC, en particular desórdenes esquizoafectivos, depresión, trastornos de ansiedad, trastornos relacionados con el estrés, trastornos del sueno, trastornos cognitivos, trastornos de la personalidad, trastornos de la alimentación, trastornos neurodegenerativos, trastornos de adicción, trastornos del ánimo, disfunción sexual, dolor y otras condiciones relacionadas con el SNC; inflamación, trastornos alérgicos; emesis; trastornos gastrointestinales, en particular el síndrome de intestino irritable (IBS); trastornos de la piel; trastornos vasoespásticos; enfermedades fibrosantes y del colágeno; trastornos relacionados con incremento o la supresión inmune y enfermedades reumáticas y control del peso corporal. Reivindicación 1: Un compuesto de acuerdo con la fórmula general (1), sales de adición con ácidos o bases aceptables para uso farmacéutico de los mismos, las formas estereoquímicamente isoméricas de los mismos, la forma de N-óxidos de los mismos y profármacos de los mismos, en donde: n es un número entero, igual a 0, 1 o 2; m es un número entero, igual a 1 o 2, con la condición de que si m es 2, entonces n sea 1; p es un número entero, igual a 1 o 2; q es un entero igual a 0 o 1; Q es O o NR3; X es un enlace covalente o un radical bivalente de fórmula -O-, -S o -NR3-; cada R3 independientemente uno del otro es H o alquilo; cada R1 independientemente uno del otro se selecciona del grupo de Ar1, Ar1-alquilo y di(Ar1)-alquilo; R2 es Ar2, Ar2-alquilo, di(Ar2)alquilo, Het1 o Het1-alquilo; Y es un enlace covalente o un radical bivalente de fórmula -C(=O)-, -SO2-;>C=CH-R o >C=N-R, donde R es CN o nitro; cada Alk representa, independientemente uno del otro, un enlace covalente; un radical hidrocarbonado saturado o no saturado, lineal o ramificado bivalente que tiene de 1 a 6 átomos de C; o un radical hidrocarbonado cíclico saturado o no saturado que tiene de 3 a 6 átomos de C; donde cada radical está opcionalmente sustituido en uno o más átomos de C con uno o más radicales fenilo, halo, ciano, hidroxi, formilo y amino; L se selecciona del grupo de H, alquilo, alquiloxi, Ar3-oxi, alquiloxicarbonilo, alquilcarboniloxi, mono- y di(alquil)amino, mono- y di(Ar3)amino, Ar3, Ar3-carbonilo, Het2 y Het2-carbonilo; Ar1 es fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada uno independientemente uno del otro seleccionado del grupo de halo, alquilo, ciano, aminocarbonilo y alquiloxi; Ar2 es naftalenilo o fenilo, cada uno opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada uno independientemente uno del otro seleccionado del grupo de halo, amino, mono- y di(alquil)amino, ciano, alquilo, hidroxi, alquiloxi, carboxilo, alquiloxicarbonilo, aminocarbonilo y mono- y di(alquil)aminocarbonilo; Ar3 es naftalenilo o fenilo, opcionalmente sustituido con 1, 2 o 3 sustituyentes, cada uno independientemente uno del otro seleccionado del grupo de alquiloxi, alquilo, halo, hidroxi, Ar1carboniloxicarbonilo, piridinilo, morfolinilo, pirrolidinilo, imidazo[1,2-alfa]piridinilo, morfolinilcarbonilo, pirrolidinilcarbonilo, amino y ciano; Het1 es un radical heterocíclico monocíclico seleccionado del grupo de pirrolilo, pirazolilo, imidazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo y piridazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de quinolinilo, quinoxalinilo, indolilo, benzimidazolilo, benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, benzofuranilo y benzotienilo; y 4a,8a-dihidro-2H-cromenil, cada radical heterocíclico puede estar sustituido opcionalmente en cualquier átomo con uno o más radicales seleccionados del grupo de halo, oxo y alquilo; Het2 es un radical heterocíclico monocíclico seleccionado del grupo de tetrahidrofuranilo, pirrolidinilo, dioxolilo, imidazolidinilo, pirrazolidinilo, piperidinilo, morfolinilo, ditianilo, tiomorfolinilo, piperazinilo, imidazolidinilo, tetrahidrofuranilo, 2H-pirrolilo, pirrolinilo, imidazolinilo, pirazolinilo, pirrolilo, imidazolilo, pirazolilo, triazolilo, furanilo, tienilo, oxazolilo, isoxazolilo, tiazolilo, tiadiazolilo, isotiazolilo, piridinilo, pirimidinilo, pirazinilo, piridazinilo y triazinilo; o un radical heterocíclico bicíclico seleccionado del grupo de benzopiperidinilo, quinolinilo, quinoxalinilo, indolilo, isoindolilo, cromenilo, benzimidazolilo, imidazo[1,2-alfa]piridinilo, benzoxazolilo, bencisoxazolilo, benzotiazolilo, bencisotiazolilo, benzofuranilo y benzotienilo, benzo[2,1,3]oxadiazolilo, imidazo[2,1-b]tiazolilo, 2,3-dihidrobenzo[1,4]dioxilo, y octahidrobenzo[1,4]dioxilo; cada radical puede estar opcionalmente sustituido con uno o más radicales seleccionados del grupo de Ar1, Ar1alquilo, Ar1alquiloxialquilo, halo, hidroxi, alquilo, alquilcarbonilo, alquiloxi, alquiloxialquilo alquiloxicarbonilo; piperidinilo, piridinilo, pirrolilo, tienilo, oxo y oxazolilo; y alquilo es un radical hidrocarbonado saturado o no saturado, lineal o ramificado que tiene de 1 a 6 átomos de C; o un radical hidrocarbonado cíclico saturado que tiene de 3 a 6 átomos de C; opcionalmente sustituido en uno o más átomos de C con uno o más radicales seleccionados del grupo de radicales fenilo, halo, ciano, oxo, hidroxi, formilo y amino.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0214835 | 2002-12-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042653A1 true AR042653A1 (es) | 2005-06-29 |
Family
ID=32668701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104779A AR042653A1 (es) | 2002-12-23 | 2003-12-22 | Derivados sustiuidos de 1- piperidin -3- il- 4- piperidin 4- -il- piperazina y su uso como antagonistas de taquiquininas |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7572786B2 (es) |
| JP (1) | JP4660198B2 (es) |
| KR (1) | KR101049075B1 (es) |
| CN (1) | CN100482229C (es) |
| AR (1) | AR042653A1 (es) |
| AU (1) | AU2003300578B2 (es) |
| CA (1) | CA2509088C (es) |
| CL (1) | CL2003002722A1 (es) |
| DE (1) | DE60317709T2 (es) |
| EA (1) | EA008774B1 (es) |
| ES (1) | ES2297275T3 (es) |
| HK (1) | HK1087924A1 (es) |
| HR (1) | HRP20050554B1 (es) |
| IL (1) | IL169337A (es) |
| JO (1) | JO2485B1 (es) |
| MX (1) | MXPA05006888A (es) |
| MY (1) | MY134383A (es) |
| NO (1) | NO331173B1 (es) |
| NZ (1) | NZ541036A (es) |
| PA (1) | PA8593201A1 (es) |
| PL (1) | PL214705B1 (es) |
| TW (1) | TWI327916B (es) |
| UA (1) | UA83474C2 (es) |
| WO (1) | WO2004056364A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| BRPI0509803A (pt) | 2004-04-13 | 2007-09-18 | Incyte Corp | derivados de piperazinilpiperidina como antagonistas de receptor de quimiocina |
| GB0417702D0 (en) * | 2004-08-09 | 2004-09-08 | Merck Sharp & Dohme | New uses |
| JP5078869B2 (ja) | 2005-03-08 | 2012-11-21 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ニューロキニン（ｎｋ１）拮抗物質としてのジアザ−スピロ−［４．４］−ノナン誘導体 |
| WO2014142761A1 (en) * | 2013-03-15 | 2014-09-18 | Nanyang Technological University | 3-piperidone compounds and their use as neurokinin-1 (nk1) receptor antagonists |
| EP3160469B1 (en) | 2014-06-25 | 2021-04-28 | Emory University | Methods of managing conditioned fear with neurokinin receptor antagonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY110227A (en) | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| NZ321575A (en) * | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
| TW531537B (en) * | 1995-12-27 | 2003-05-11 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives |
| FR2791346B3 (fr) * | 1999-03-25 | 2001-04-27 | Sanofi Sa | Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant |
| WO2001030348A1 (en) * | 1999-10-25 | 2001-05-03 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
| GB0025354D0 (en) * | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
| GB2368098B (en) | 2000-10-20 | 2004-09-15 | Gw Pharmaceuticals Ltd | Secure dispensing of materials |
| US6642226B2 (en) | 2001-02-06 | 2003-11-04 | Hoffman-La Roche Inc. | Substituted phenyl-piperidine methanone compounds |
| JP4389478B2 (ja) * | 2002-05-29 | 2009-12-24 | 田辺三菱製薬株式会社 | 新規ピペリジン誘導体 |
| MY141736A (en) * | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
| AU2002368487A1 (en) * | 2002-12-23 | 2004-07-14 | Janssen Pharmaceutica N.V. | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists |
| KR20060006098A (ko) * | 2003-06-10 | 2006-01-18 | 얀센 파마슈티카 엔.브이. | 오피오이드 진통제와 배합된 치환된1,4-디-피페리딘-4-일-피페라진 유도체 및 오피오이드계치료와 관련된 통증 및 부작용 치료용으로 이들의 용도 |
-
2003
- 2003-12-15 JO JO2003173A patent/JO2485B1/en active
- 2003-12-17 KR KR1020057009752A patent/KR101049075B1/ko not_active IP Right Cessation
- 2003-12-17 JP JP2004561502A patent/JP4660198B2/ja not_active Expired - Fee Related
- 2003-12-17 UA UAA200505307A patent/UA83474C2/uk unknown
- 2003-12-17 DE DE60317709T patent/DE60317709T2/de not_active Expired - Lifetime
- 2003-12-17 EA EA200501040A patent/EA008774B1/ru not_active IP Right Cessation
- 2003-12-17 PL PL376075A patent/PL214705B1/pl unknown
- 2003-12-17 NZ NZ541036A patent/NZ541036A/en not_active IP Right Cessation
- 2003-12-17 MX MXPA05006888A patent/MXPA05006888A/es active IP Right Grant
- 2003-12-17 CN CNB2003801070088A patent/CN100482229C/zh not_active Expired - Fee Related
- 2003-12-17 US US10/540,045 patent/US7572786B2/en not_active Expired - Fee Related
- 2003-12-17 CA CA2509088A patent/CA2509088C/en not_active Expired - Fee Related
- 2003-12-17 ES ES03813610T patent/ES2297275T3/es not_active Expired - Lifetime
- 2003-12-17 WO PCT/EP2003/051035 patent/WO2004056364A1/en active IP Right Grant
- 2003-12-17 AU AU2003300578A patent/AU2003300578B2/en not_active Ceased
- 2003-12-19 MY MYPI20034910A patent/MY134383A/en unknown
- 2003-12-19 PA PA20038593201A patent/PA8593201A1/es unknown
- 2003-12-22 CL CL200302722A patent/CL2003002722A1/es unknown
- 2003-12-22 AR ARP030104779A patent/AR042653A1/es unknown
- 2003-12-22 TW TW092136344A patent/TWI327916B/zh not_active IP Right Cessation
-
2005
- 2005-06-15 HR HRP20050554AA patent/HRP20050554B1/hr not_active IP Right Cessation
- 2005-06-21 IL IL169337A patent/IL169337A/en not_active IP Right Cessation
- 2005-07-22 NO NO20053598A patent/NO331173B1/no not_active IP Right Cessation
-
2006
- 2006-07-24 HK HK06108211.0A patent/HK1087924A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042651A1 (es) | Derivados de 1-piperidin - 4- il- 4- pirrolidin -3- il- piperazina sustituidos y su uso como antagonistas de neuroquininas | |
| AR041545A1 (es) | Derivados sustituidos de 1,4-di-piperidin-4 il-piperazina y su uso como antagonistas de neuroquininas | |
| CA2509406A1 (en) | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists | |
| AR044543A1 (es) | Derivados de pirazolo-quinazolina, un procedimiento para su preparacion y su uso como inhibidor de quinasa | |
| AR051090A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR037647A1 (es) | Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina | |
| AR051094A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR051091A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| NO20051694L (no) | Heterosykliske forbindelser | |
| AR051026A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| BR0309309A (pt) | Antagonistas de receptor de trombina tricìclicos | |
| AR064547A1 (es) | Derivados de azaspiro como antagonistas del receptor v1a | |
| AR048939A1 (es) | Derivados de fenol y tiofenol 3 - o 4 - monosustituidos utiles como ligandos de h3; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de trastornos neurologicos e inflamatorios. | |
| AR051294A1 (es) | Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| CA2561944A1 (en) | Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists | |
| EA201190119A1 (ru) | ПРОИЗВОДНЫЕ ТРИАЗОЛОПИРИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ МАР-КИНАЗЫ p38 | |
| CA2561975A1 (en) | Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists | |
| AR054231A1 (es) | Composiciones farmaceuticas | |
| AR052342A1 (es) | Derivados sustituidos de triazolona,tetrazolona e imidazolona con actividad selectiva antagonista de alfa2c-adenoreceptores | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| AR045913A1 (es) | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina | |
| AR042653A1 (es) | Derivados sustiuidos de 1- piperidin -3- il- 4- piperidin 4- -il- piperazina y su uso como antagonistas de taquiquininas | |
| AR117576A1 (es) | Derivados de sulfinilaminobenzamida y sulfonilaminobenzamida | |
| AR044490A1 (es) | Formulaciones para tratamientos de base opioidea para el dolor que comprenden derivados sustituidos de 1,4 - di- piperidin - 4- il- piperazina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |